Workflow
AstraZeneca(AZN)
icon
Search documents
AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales
Investopedia· 2024-07-25 13:01
Key TakeawaysAstraZeneca's second-quarter earnings beat expectations Thursday, and the drugmaker also lifted its guidance.Like its COVID-19 vaccine manufacturing colleagues Pfizer and Johnson & Johnson, AstraZeneca's revenue from vaccines fell year-over-year.During the quarter, the company said at its annual investor day that it believes the drugs in its development pipeline can boost revenue to $80 billion annually by 2030, compared to $45 billion in 2023. AstraZeneca (AZN) posted better-than-expected resu ...
Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca
Prnewswire· 2024-07-23 15:17
Pinetree to receive up to $45 million in upfront and near-term payments, with a total deal value of over $500 million including potential additional development and commercial milestone payments CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the "Company"), a biotechnology company pioneering next generation targeted protein degraders (TPD) to combat drug resistance in oncology and beyond, today announced it has entered into an exclusive option and global license a ...
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
ZACKS· 2024-07-22 15:50
AstraZeneca (AZN) will report its second-quarter earnings on Jul 25, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.57 billion and 96 cents per share, respectively. Earnings estimates for AstraZeneca have risen from $4.04 per share to $4.05 per share for 2024 and from $4.67 per share to $4.69 per share for 2025 over the past 30 days.Image Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been mixed, with the compan ...
AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings
Seeking Alpha· 2024-07-18 17:50
Shutter2U Investment Overview In the first of my two most recent pieces of coverage for Seeking Alpha on AstraZeneca PLC (NASDAQ:AZN), the Anglo / Swedish Pharma giant, I gave the company and its stock a “buy” recommendation in February. This was after a sell-off in response to a Q4 2023 earnings miss created a buying opportunity. Then, in late May, I gave it a “hold” recommendation, shortly after the company had revealed ambitious plans to exceed $80bn in top-line revenues by 2030. AstraZeneca stock is ...
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
ZACKS· 2024-07-18 15:45
AstraZeneca’s (AZN) stock has risen 18.4% so far this year, underperforming an increase of 23.4% for the industry, as seen in the chart below. AstraZeneca’s stock has, however, outperformed the sector as well as the S&P 500.AstraZeneca Stock Performance Image Source: Zacks Investment ResearchAstraZeneca boasts a diversified geographical footprint as well as product portfolio with several blockbuster medicines. AstraZeneca now has 12 blockbuster medicines in its portfolio with sales exceeding $1 billion, inc ...
AstraZeneca Closes Acquisition of Amolyt Pharma
GlobeNewswire News Room· 2024-07-15 06:00
Core Insights - Amolyt Pharma has been acquired by AstraZeneca for a total consideration of up to $1.05 billion, enhancing AstraZeneca's rare disease pipeline and expanding its bone metabolism franchise [3]. Group 1: Acquisition Details - The acquisition includes an upfront payment of $800 million at deal closing, with an additional contingent payment of $250 million based on achieving a specified regulatory milestone [3]. - The acquisition is expected to bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline, particularly with the addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide [2]. Group 2: Product and Pipeline Expansion - Enebo paratide (AZP-3601) is designed to address hypoparathyroidism, a condition caused by a deficiency in parathyroid hormone (PTH) production, leading to significant calcium and phosphate dysregulation [2]. - Amolyt Pharma's portfolio also includes AZP-3813, a peptide growth hormone receptor antagonist aimed at treating acromegaly, indicating a focus on rare endocrine diseases [4].
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
ZACKS· 2024-07-02 16:00
AstraZeneca (AZN) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its PD-L1 inhibitor Imfinzi (durvalumab) as a treatment for certain patients with primary advanced or recurrent endometrial cancer.The CHMP recommended the approval of Imfinzi plus chemotherapy, followed by Imfinzi and Lynparza as a first-line treatment for patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.The CHMP ...
3 Set-It-and-Forget-It Stocks for Lasting Financial Security
Investor Place· 2024-07-02 14:42
One of the greatest forces in wealth-building is the power of compounding. That is why every portfolio needs some set-it-and-forget-it stocks. When you find a good compounder, you should hold it forever.It is well known that investors do poorly timing the market. Due to the psychological nature of investing, most investors tend to buy at the top and sell at the bottom. As a result, they end up underperforming the market indices.Similarly, trying to time the tops and bottoms in the best-in-class compounders ...
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Investor Place· 2024-06-26 18:11
While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks.First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressing diseases an ...
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
ZACKS· 2024-06-26 18:01
AstraZeneca (AZN) announced positive results from the phase III NIAGARA study, which evaluated Imfinzi in patients with muscle-invasive bladder cancer (MIBC).Study participants who were enrolled in the NIAGARA study were randomized to receive Imfinzi plus chemotherapy or chemotherapy alone before cystectomy (bladder removal surgery), followed by Imfinzi or no further treatment after surgery.The study achieved statistically significant and clinically meaningful improvement in its primary endpoint of event-fr ...